Anbio Biotechnology NNNN
What this company does
Written from the business description in Anbio Biotechnology's annual report to the U.S. Securities and Exchange Commission, filed 7 April 2026. Every sentence was checked against that document before publication.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity produced 27 cents of profit this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITDA $B | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | · |
| Net income $B | 0.0 | 0.0 | 0.0 | 0.0 |
| EPS, diluted $ | 0.15 | 0.06 | 0.10 | 100112.00 |
| Dividend / sh $ | · | · | · | · |
| Payout % | · | · | · | · |
| ROE % | 27.0 | 14.8 | 16.5 | 79.8 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 4 of 19 fiscal years. 77 checks could not be computed.